(PJP) Dynamic Pharmaceuticals - Overview
Etf: Pharmaceutical, Stocks, 30
Dividends
| Dividend Yield | 1.15% |
| Yield on Cost 5y | 1.36% |
| Yield CAGR 5y | 11.51% |
| Payout Consistency | 85.5% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 15.5% |
| Relative Tail Risk | 5.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 14.54 |
| Character TTM | |
|---|---|
| Beta | 0.532 |
| Beta Downside | 0.568 |
| Drawdowns 3y | |
|---|---|
| Max DD | 16.27% |
| CAGR/Max DD | 0.76 |
Description: PJP Dynamic Pharmaceuticals January 02, 2026
The Invesco Dynamic Pharmaceuticals ETF (NYSE ARCA: PJP) seeks to track an index of 30 U.S. pharmaceutical companies, allocating at least 90% of its assets to the constituent stocks. Because the index is limited to a relatively small number of firms, the fund is classified as non-diversified, meaning concentration risk is higher than in broader health-care ETFs.
Key metrics (as of the latest filing) include an expense ratio of 0.61% and a weighted-average market-cap of roughly $55 billion, indicating a tilt toward large-cap, established drugmakers. The top five holdings typically comprise industry leaders such as Pfizer, Johnson & Johnson, and Merck, together accounting for about 35% of assets. Recent sector drivers-an aging U.S. population (+1.8% annual growth), a 5% YoY increase in prescription drug spending, and robust R&D pipelines (U.S. pharma R&D spend hit $210 billion in 2023)-suggest a favorable backdrop, though regulatory pricing pressure and generic competition remain material uncertainties.
For a deeper, data-rich analysis of PJP’s risk-adjusted performance and valuation multiples, you might find ValueRay’s interactive dashboards useful.
What is the price of PJP shares?
Over the past week, the price has changed by +1.40%, over one month by +2.71%, over three months by +10.84% and over the past year by +26.29%.
Is PJP a buy, sell or hold?
What are the forecasts/targets for the PJP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 119.5 | 11.4% |
PJP Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 395.8m USD (395.8m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 395.8m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 395.8m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.87% (E(395.8m)/V(395.8m) * Re(7.87%) + (debt-free company))
Discount Rate = 7.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)